Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment.
Because patients with type 2 diabetes are at high risk for cardiovascular events, lipid abnormalities in these patients should be aggressively and efficiently treated. What is the rationale behind such an approach, and what are the goals of therapy? Dr Marcus addresses these questions and provides up-to-date recommendations for lipid-lowering treatment.
Marcus
A O
AO
Division of Diabetes, Endocrinology, and Hypertension, Department of Medicine, University of Southern California School of Medicine, Los Angeles, USA. aomarcus@aol.com
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism / Q000517:prevention & control; D018752:Diet, Fat-Restricted; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008403:Mass Screening / Q000379:methods; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000379:methods; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D014280:Triglycerides